Related Experiment Video

Updated: Aug 12, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.1K

Nectin-4: a Tumor Cell Target and Status of Inhibitor Development

Wafa Bouleftour1, Paul Sargos2, Nicolas Magne3,4

  • 1Department of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.

Current Oncology Reports
|January 25, 2023
PubMed
Abstract

Insights

Innovative antibody-drug conjugates targeting Nectin-4 show promise in solid tumors, particularly urothelial carcinoma. Understanding resistance mechanisms, like P-gp upregulation, is crucial for optimizing treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) targeting Nectin-4 have emerged as a significant therapeutic strategy.
  • Nectin-4 expression is heterogeneous across molecular subtypes, particularly in urothelial cancers.
  • Enfortumab vedotin demonstrates promising efficacy in various solid tumors, including rare malignancies.

Purpose of the Study:

  • To review the current literature on anti-Nectin-4 therapies in solid tumors.
  • To investigate the mechanisms underlying resistance to anti-Nectin-4 treatments.
  • To highlight novel therapeutic associations and future research directions.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of Nectin-4 expression patterns.
  • Investigation of resistance mechanisms, including P-glycoprotein (P-gp) expression.

Main Results:

  • Anti-Nectin-4 ADCs show notable efficacy, especially in urothelial carcinoma.
  • Heterogeneity in Nectin-4 expression impacts treatment response.
  • Preclinical models suggest P-gp upregulation as a potential resistance mechanism.

Conclusions:

  • Further research is essential to elucidate sensitivity and resistance to anti-Nectin-4 therapies.
  • Optimizing treatment strategies requires a deeper understanding of Nectin-4 biology and resistance pathways.
  • Enfortumab vedotin offers significant therapeutic potential for managing diverse solid tumors.
Keywords:
Antidrug conjugateBiomarkerHeterogeneityMalignanciesNectin-4Targeted therapy

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K